Drug Trial News

RSS

AKT inhibitor shows promise in a trial matching new treatments to cancer patients based on genetic make-up of tumors

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink.

27 Oct 2022

A study of Moderna's COVID vaccine in children aged 6 months to 5 years

In a recent study published in the New England Journal of Medicine, researchers presented the findings of the ongoing KidCOVE trial in the United States (US).

23 Oct 2022

Three-dose regimen of HEPLISAV-B vaccine fully protects people living with HIV, data shows

The AIDS Clinical Trials Group (ACTG), the world's largest HIV research network whose focus has expanded to include evaluating outpatient treatment for COVID-19, today presented a session demonstrating that a three-dose regimen of the HEPLISAV-B vaccine fully protected people living with HIV at IDWeek 2022, taking place in Washington D.C. from October 19-22, 2022.

20 Oct 2022

Three-dose course of the hepatitis B vaccine fully protects adults living with HIV

A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C.

20 Oct 2022

Mass General Brigham sites announce participation in phase 3 trial of monkeypox treatment

Massachusetts General Hospital and Brigham and Women's Hospital, the founding members of Mass General Brigham, today announced their participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat (TPOXX) for the treatment of human monkeypox.

19 Oct 2022

$Over-the-counter aspirin effective in preventing blood clots following surgery to repair bone fractures$

Over-the-counter aspirin effective in preventing blood clots following surgery to repair bone fractures

Patients who have surgery to repair bone fractures typically receive a type of injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots, but a new clinical trial found that over-the-counter aspirin is just as effective.

14 Oct 2022

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF).

13 Oct 2022

Enterin and Parkinson's Virtual Biotech collaborate to study the effects of ENT-01 on PD-associated dementia

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson's Virtual Biotech, the drug development and discovery arm of Parkinson's UK.

13 Oct 2022

Clinical trial to evaluate antiviral drug for monkeypox begins in the Democratic Republic of the Congo

A clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX, in adults and children with monkeypox has begun in the Democratic Republic of the Congo (DRC).

12 Oct 2022

Clinical trial to test the safety, efficacy of bacteriophages for treating P. aeruginosa infections in CF patients

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs and other organs in the body.

11 Oct 2022

Oxford researchers report findings from Phase 1 clinical trial of intranasal COVID-19 vaccine

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the safety and immune response of an intranasally-administered vaccine against COVID-19.

11 Oct 2022

Clinical trials of novel COVID-19 vaccine developed in Brazil to begin soon

Testing on humans of a novel COVID-19 vaccine developed in Brazil will begin this year. It performed well in animal trials, as reported in an article published in August in Nature Communications.

6 Oct 2022

Early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis begins

Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs.

4 Oct 2022

Eligibility criteria lack clarity, justification for excluding people with disabilities from clinical trials

Despite constituting the largest minority group in the U.S. and expressing interest in participating in clinical trials, people with disabilities remain excluded.

3 Oct 2022

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.

29 Sep 2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate).

27 Sep 2022

First data on Pfizer-BioNTech's Omicron BA.4/5 combination vaccine

In a recent study posted to the bioRxiv* preprint server, researchers from Germany and the United States analyzed the association between exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/BA.5 spike glycoprotein and pan-Omicron neutralization.

27 Sep 2022

Study looks at boosting with variant-derived COVID vaccine

In a recent study posted to bioRxiv*, researchers at Washington University School of Medicine, St. Louis, demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster elicits robust germinal center (GC) B cell responses.

26 Sep 2022

Designing a new treatment to treat migraine effectively

In this interview, we speak to Mudra Kapoor, Vice President of Global Medical Affairs for Neuroscience at AbbVie, about atogepant, their new treatment option for migraine.

From AbbVie 26 Sep 2022

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

In a recent study posted to the medRxiv* preprint server, researchers in the United States described the safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), tested in PREVENT-19 — a phase 3, randomized, placebo-controlled, observer-blinded trial among 12- to 17-year-old adolescents in the United States (U.S).

25 Sep 2022

Previous
1
...
41
42
43
44
45
46
47
...
1156
Next